This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

RUDOLPH G. MRAZEK, M.D.; STEVEN G. ECONOMOU, M.D.

AMA Arch Surg. 1959;78(1):51-55.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Nitromin (methyl-bis[β-chloroethyl]amine-N-oxide hydrochloride) is an alkylating agent which was developed during the search for compounds which would have the therapeutic effect of nitrogen mustard with lessened toxicity. It was first synthesized by Stahmann and Bergmann¹ in 1946, the by oxidation of nitrogen mustard and wfirst as applied to animal and clinical investigations by Yoshida and Ishidate and coworkers.² These workers found that 4of 0% rats with 4-day-old Yoshida ascites sarcoma implantations could be completefreed ly of tumor by intraperitoneal injections totaling 10 to 20 mg. per kilogram of body weight of Nitromin given every other dfor ay four to five weeks. If the treatment was started immediately after the tumor implantation, a higher percentage was cureif it d; Was started seven days after inoculation, only a small percentage survived. These findings have been confirmed Druckrey,by³ in Germany, who found the drug most effective, and with . . . [Full Text PDF of this Article]

Author Affiliations
Chicago

Department of Surgery, University of Illinois College of Medicine.

Footnotes
Submitted for publication July 1, 1958.

The Nitromin used in this study was supplied by Takeda Pharmaceutical Industries, Ltd., Osaka, Japan.

This study was supported in part by research grant CY-3157 from the National Cancer Institute of the National Institute of Health.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?